恒瑞医药股份回购进展公告详细解读
要点概览
- 回购计划总金额：人民币 10 亿元至 20 亿元
- 回购用途：用于员工持股计划或股权激励
- 回购实施期限：2025 年 8 月 20 日至 2026 年 8 月 19 日
- 累计已回购股份：1,205.62 万股，占总股本 0.18%
- 累计已耗资：77,198.09 万元，实际回购价区间 53.52 元/股~70.00元/股
- 最新进展：2026 年 4 月回购 10.88 万股，耗资 607.27 万元
公告内容详细解读
一、回购基本情况
江苏恒瑞医药股份有限公司（“公司”）于 2025 年 8 月 20 日召开董事会，通过了以自有资金回购 A 股股份的方案。
本次回购的资金总额不低于 10 亿元且不超过 20 亿元，回购价格不超过 90.85 元/股（含），期限为 12 个月。
此次回购股份将专用于实施 A 股员工持股计划或股权激励，并未用于减少注册资本或可转债转换。
本次回购方案首次披露时间为 2025 年 8 月 21 日，回购实施时间为 2025 年 8 月 20 日至 2026 年 8 月 19 日。
二、回购进展情况
截至 2026 年 4 月 30 日，公司通过上海证券交易所集中竞价交易方式，累计回购股份 1,205.62 万股，占公司总股本的 0.18%，已支付金额合计 77,198.09 万元，回购价格区间为 53.52 元/股至 70.00 元/股。
2026 年 4 月份，回购股份 10.88 万股，占总股本 0.002%，最高成交价 55.99 元/股，最低成交价 55.69 元/股，耗资 607.27 万元。
三、对股东和股价的影响
- 回购用于员工持股和激励计划： 大规模员工持股和激励计划有助于增强员工凝聚力和公司治理，提升公司长期价值，通常被市场视为利好消息。
- 回购进度稳步推进： 截至目前已完成最高 20 亿元回购额度的 77%，反映公司现金流充沛、对未来发展有信心。
- 回购价格区间： 实际回购价区间为 53.52 元/股至 70.00 元/股，显示公司对当前股价的认可，有望对二级市场股价形成支撑。
- 后续进展： 公司承诺将根据市场情况择机继续实施回购，并及时履行信息披露义务，投资者需关注后续公告。
投资者需关注的风险与事项
- 回购计划的实施进度、回购价格变化可能对市场情绪和股价形成影响。
- 回购股份将用于员工持股计划或股权激励，不会直接减少公司注册资本。
- 公司将严格按照相关法律法规和回购方案执行，投资者需注意投资风险。
结语
恒瑞医药本次回购进展顺利，反映公司治理稳健、现金流充裕及对未来的信心。大额回购和员工激励计划整体利好公司中长期发展，对股价有一定支撑作用。建议投资者持续关注后续回购进展及相关公告，理性判断投资风险。
免责声明：本文仅为信息解读，不构成任何投资建议。股市有风险，投资需谨慎。
English version:
Detailed Analysis of Hengrui Pharma Share Buyback Progress Announcement
Key Points Overview
- Total Buyback Amount: RMB 1 billion to 2 billion
- Purpose: For employee shareholding plan or equity incentives
- Buyback Period: August 20, 2025 to August 19, 2026
- Cumulative Shares Repurchased: 12.0562 million shares, 0.18% of total equity
- Cumulative Amount Spent: RMB 771.9809 million; buyback price range: RMB 53.52/share to RMB 70.00/share
- Latest Progress: 108,800 shares repurchased in April 2026, spending RMB 6.0727 million
Detailed Interpretation of the Announcement
1. Basic Buyback Situation
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“the Company”) convened a board meeting on August 20, 2025, and approved a plan to use self-owned funds to repurchase A-shares.
The total buyback fund is not less than RMB 1 billion and not more than RMB 2 billion. The buyback price does not exceed RMB 90.85/share (inclusive), and the period is 12 months.
Shares repurchased will be used exclusively for the A-share employee stock ownership plan or equity incentive, not to reduce registered capital or convert bonds.
The plan was first disclosed on August 21, 2025, and implementation is from August 20, 2025 to August 19, 2026.
2. Buyback Progress
As of April 30, 2026, the company has cumulatively repurchased 12.0562 million shares (0.18% of total equity) through the SSE centralized bidding system, with a total expenditure of RMB 771.9809 million. The buyback price range was RMB 53.52/share to RMB 70.00/share.
In April 2026, 108,800 shares were repurchased (0.002% of total equity) at a highest price of RMB 55.99/share and lowest of RMB 55.69/share, costing RMB 6.0727 million.
3. Impact on Shareholders and Share Price
- Employee Plan and Incentives: Large-scale employee shareholding and incentive plans help enhance staff cohesion and corporate governance, boosting long-term value—usually seen as a positive by the market.
- Steady Buyback Progress: About 77% of the maximum buyback amount has been utilized, reflecting strong cash flow and management’s confidence in the future.
- Buyback Price Range: The actual buyback price range reflects management’s recognition of the current share price, with potential to support the market price.
- Ongoing Disclosure: The company promises to continue buybacks as market conditions permit and fulfill disclosure obligations—investors should keep track of future updates.
Risks and Matters for Investors to Note
- The progress and pricing of the buyback may affect market sentiment and the share price.
- Repurchased shares are for employee plans/incentives, not for direct capital reduction.
- The company will execute the plan according to rules—investors are advised to be aware of investment risks.
Conclusion
Hengrui’s steady buyback progress demonstrates healthy governance, ample cash flow, and confidence in the future. The large-scale buyback and incentive plan are overall positive for medium- and long-term development and could support the share price. Investors are advised to monitor future buyback progress and announcements and assess risks rationally.
Disclaimer: This article is for information only and does not constitute investment advice. The stock market is risky—invest cautiously.
